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INTRODUCTION
Clinical bone marrow transplantation (BMT) has been
expanding as a treatment modality for acquired hemato-
poietic disorders and malignancies [1]. Higher incidences of
graft failure after BMT with T cell–depleted (TCD) mar-
row to avoid graft-versus-host disease (GVHD) and failure
in multiply transfused recipients have fostered significant
clinical concern regarding graft rejection [2-4]. Rates of
graft rejection using TCD marrow are high when HLA-
disparate and HLA-identical (50% to 75% and 10% to
30%, respectively) marrow is used [5]. Whereas consider-
able efforts have examined the nature of the cells responsi-
ble for major histocompatibility complex (MHC)-mis-
matched marrow graft resistance, the molecular pathways
used by effector cells mediating progenitor cell rejection
are still unclear [6-14].
After allogeneic BMT across MHC disparities in mice,
both natural killer (NK) cells and T cells play important
roles [7-12]. CD4+ and CD8+ T cells have been shown to
reject MHC class II or I disparate TCD marrow, respec-
tively [11]. However, effector modalities were not examined
in these studies. Nonetheless, resistance to engraftment is
generally considered to be mediated by cytotoxic T cells
because (1) antidonor cytotoxic T lymphocytes (CTLs)
have been identified from primates and clinical transplant
recipients rejecting hematopoietic grafts [15,16] and (2)
murine CTL clones were shown to be capable of transfer-
ring resistance to nonresistant recipients [17]. Although
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these types of ﬁndings implicate cytotoxicity as a potentially
important effector pathway, there is no direct evidence of a
role for this effector modality in this process. We are inter-
ested in addressing questions concerning which effector
mechanisms are used by host cells involved in resistance to
progenitor cell engraftment [18]. The current studies used
a murine model in which short-term marrow allograft resis-
tance was examined using a sensitive in vitro assay to detect
progenitor cell presence by colony formation in vitro [19].
Resistance was demonstrated to be dependent on the previ-
ous priming of MHC-matched marrow transplant recipients
to donor non-MHC antigens. The resistance mechanism
clearly discriminated between donor and syngeneic pro-
genitors after mixed marrow transplants and could be efﬁ-
ciently transferred by T cells to naive recipients. Notably,
the resistance was not impaired in animals unable to medi-
ate cell-mediated cytotoxicity involving perforin-dependent
or FasL-dependent pathways. The present findings there-
fore indicate that a single cytotoxic effector pathway alone
is sufficient to effect marrow allograft resistance or that
nonperforin and non-FasL effector mechanisms mediate
resistance in this T cell–dependent model.
MATERIALS AND METHODS
Mice
C57BL/6J (B6, H-2b), B6.SJL-Cd45a Pepb/boyJ (Ly5.1,
H-2b), BALB.B (H-2b), C3H.SW (H-2b), and B6.Smn
C3H-gld (B6-gld/gld, H-2b) mice were obtained from Jack-
son Laboratory (Bar Harbor, ME). B6-perforin–/– (H-2b)
mice were generously provided by Dr. Eckhard R. Podack
and were maintained in pathogen-free conditions in the
Department of Microbiology and Immunology at the Uni-
versity of Miami School of Medicine. Mice were aged 8 to
16 weeks and sex-matched for each experiment.
Priming Against Non-MHC Alloantigens
Spleen, lymph node, and thymus tissue were aseptically
removed from C3H.SW or BALB.B donor mice. Single-cell
suspensions were prepared in the absence of exogenous
serum, washed, and counted. Cells were adjusted to a con-
centration of 6  107/mL, and 0.5 mL of the suspension was
administered into B6 mice by intraperitoneal and intrader-
mal (multiple) injection. Some groups of animals were
primed more than 1 time before receiving a BMT.
Bone Marrow Transplantation
Femurs and tibias were harvested from appropriate
donors. Bone marrow cells (BMCs) were flushed using a
26-gauge needle with RPMI-1640, the cell suspensions
obtained were washed, and the nucleated BMCs were
counted. T cells were removed from the donor marrow by
incubating the suspension with anti-Thy1.2 monoclonal
antibody (HO13.4 ascites diluted 1:200) followed by 10%
vol/vol Low-Tox M rabbit complement (Accurate Chemi-
cal and Scientific, Westbury, NY) at 37°C for 45 minutes.
Flow cytometric analysis demonstrated that the level of
T cells present was reduced from approximately 2.0% in
nondepleted marrow to below the level of detection (ie,
<0.2%) (data not shown). Recipient mice were exposed to
9.0 Gy lethal total body irradiation (TBI) from an open-beam
60Co -source at a dose rate of 50 cGy/min. Twenty-four
hours later, 2.0  106 TCD BMCs were infused into the
lateral tail vein of irradiated recipients. Recipients (2 to 4
per group) were given fluid support by intraperitoneal
injection of 0.5 mL sterile phosphate-buffered saline for 1
to 3 days after transplant. Recipient mice were maintained
on acidified/antibiotic water (pH <2.2, 100 mg/L
neomycin sulfate, 10 mg/L polymixin B sulfate).
Adoptive Transfer of Allograft Resistance to
Unprimed Recipients
B6 mice were primed to C3H.SW or BALB.B as
described above. Spleen and lymph nodes were aseptically
removed from these primed mice, and single-cell suspen-
sions were prepared, washed, and counted. NK cells were
removed by in vivo depletion of B6 donors using antibody
against NK1.1 (PK136 ascites, 100 µL intraperitoneally)
injected 48 hours before collecting spleen and lymph node
cells (LNCs). Aliquots of cells from these donors were also
treated with anti-NK1.1 monoclonal antibody (mAb) plus
complement in vitro before transfer. Flow cytotoxic analysis
of these NK cell–depleted populations with fluorescein
isothiocyanate (FITC)-conjugated anti-hamster immuno-
globulin (Ig) identified <1.0% staining cells. To delete
T cells, spleen and LNCs from B6 mice primed to donor
antigen (with or without anti-NK1.1 mAb in vivo treat-
ment) were treated with anti-Thy1.2 mAb and complement
as described above. Cells were then stained with anti-CD3
FITC and analyzed by flow cytometry (<4.0% CD3+ cells
were present; data not shown). Desired numbers of these
cells or unfractionated populations from primed or unprimed
(control) B6 mice were infused intravenously into unprimed
B6 mice 48 hours before BMT (Figure 1). Twenty-four
hours later, these mice were administered 9.0 Gy TBI as
described above. Recipients received a BMT containing 2 
106 TCD C3H.SW marrow 24 hours later.
In Vitro Colony-Forming Unit-Granulocyte/Macrophage
and Colony-Forming Unit–Interleukin-3 Assay
The colony-forming unit-granulocyte/macrophage
(CFU-GM) and colony-forming unit-interleukin-3 (CFU-
Figure 1. Model system to adoptively transfer marrow allograft resis-
tance. Naive syngeneic B6 mice were injected intravenously with desired
cell populations. One day later, mice received total body irradiation (TBI)
as indicated. Bone marrow transplantation (BMT) was performed as
described in “Materials and Methods” 1 day after TBI. Colony-forming
activity in spleen cells was assessed (CFU assay) 5 days after BMT.
–2 –1 0 5
B6 primed cells 9.0 Gy TBI BMT CFU Assay
B6 naive cells
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IL-3) assay used was a modification of a previously
reported method described in a prior study [19]. Briefly,
recipients were killed 5 days after BMT, and nucleated
spleen cells were pooled and counted. The spleen cells (2
 105) were cultured in 1 mL of a mixture containing -
modification of Eagle’s medium with nucleosides (-
MEM), 0.86% methylcellulose, 30% fetal calf serum,
250 µmol/L 2-mercaptoethanol, 2 mmol/L L-glutamine,
100 U/mL penicillin, 100 µg/mL streptomycin, and 50
U/mL recombinant murine granulocyte-macrophage
colony-stimulating factor or IL-3 (Biosource Interna-
tional, Camarillo, CA). Cultures were established in tripli-
cate and maintained at 37°C in humidified air with 5%
CO2 for 4 days. Cell aggregates containing ≥25 cells were
scored as individual colonies (CFU) on day 4 of culture.
Results are presented as average numbers of CFU-GM or
CFU-IL-3 ± SD per group. In each experiment presented,
the difference between the CFU values obtained from
primed mice compared with the numbers obtained from
naive mice of the same strain were statistically significant
(2-tailed t test: P < .05) and therefore were not included in
the tables or figures.
RESULTS
Recipient Priming Is Required for Strong Resistance
to MHC-Matched Allogeneic Bone Marrow
Spleen cells from lethally irradiated unprimed B6
(B6naive) patients who received 2  10
6 TCD MHC-
matched C3H.SW marrow reproducibly contained large
numbers of CFU-GM and CFU-IL-3 5 days after BMT
(Table 1). Spleen cell cultures established from B6 recipi-
ents 5 days after BMT who had been primed 1 or 2 times
with donor C3H.SW (B6C3H.SW) cells at least 3 weeks
before transplant were essentially devoid of CFU-GM and
CFU-IL-3 activity. These results demonstrate that in con-
trast to the resistance detected across MHC and/or
hematopoietic histoincompatible loci disparities, efficient
host resistance against MHC-matched allogeneic marrow
grafts using 2  106 TCD marrow requires priming to
donor alloantigens.
Allograft Resistance Is Transferable and T-Cell
Dependent
B6 mice primed 2 times to C3H.SW antigens were used
as donors to assess whether the resistance to allogeneic mar-
row was transferable to unprimed recipients. Single-cell sus-
pensions prepared from the spleens of these primed or naive
B6 mice were infused into naive B6 recipients 24 hours
before TBI (Figure 1). The transfer of 7.5  107 spleen cells
from B6C3H.SW mice, but not spleen cells from unprimed B6
donors, effectively induced resistance against C3H.SW
TCD transplanted marrow (Table 2, experiment 1). To
assess the involvement of T cells, experiments were per-
formed using CD3+-enriched populations (Table 2, experi-
ments 2 and 3). Spleen and LNC suspensions from B6
donors primed 2 times to C3H.SW were passed over T-cell
enrichment columns to remove B cells and accessory popu-
lations. Resistance was transferred using 15 to 20  106
CD3+ cells enriched to >93%.
Because NK1.1-expressing cells have been found to con-
tribute to resistance against murine marrow allografts, an
adoptive transfer experiment was performed to assess involve-
ment in the present model. B6 mice primed 1 time against a
second MHC-matched allogeneic donor strain (ie, BALB.B)
also efﬁciently resisted a subsequent marrow allograft (Table
1). Transfer of spleen and LNCs containing 2  107 CD3+ T
cells from these B6 (anti-BALB.B) primed mice inhibited 50%
of the CFU activity measured after transfer of 2  107 CD3+
T cells from unprimed B6 mice. Before transfer, in vitro
depletion of Thy1.2+ cells completely eliminated this inhibi-
tion (Figure 2). A group of BALB.B-primed B6 mice were
administered anti-NK1.1 mAb 3 days before collection of
spleen cells and LNCs. Aliquots of these cells containing 2 
107 CD3+ cells were further depleted of NK1.1+ cells by in
vitro treatment with anti-NK1.1 mAb plus complement. Less
than 1% residual NK1.1-expressing cells (stained with anti-
hamster Ig) were detected in these populations. No loss of
resistance was detected (3 of 3 experiments) following transfer
of the CD3+ NK1.1– cells (Figure 2). In contrast, no resistance
was detected after Thy1.2 depletion of this population. In total,
these ﬁndings demonstrated that the resistance generated (1)
is dependent on priming to non-MHC minor histocompati-
Table 1. Recipient Priming Is Required for Efﬁcient Resistance to Progenitor Cells From Minor Histocompatibility Antigen Disparate Donors*
Recipients Transplanted CFU-GM/Well Average CFU-IL-3/Well Average
With 2  106 1 2 3 CFU-GM ± SD† 1 2 3 CFU-IL-3 ± SD†
Experiment 1
B6naive 79 69 97 81.7 ± 14.2 109 121 247 159 ± 76.4
B6C3H.SW 1 primed‡ 0 0 3 1 ± 1.7 1 4 0 1.7 ± 2.1
B6C3H.SW 2 primed§ 0 0 0 0 0 0 0 0
Experiment 2
B6naive 119 127 115 120.3 ± 6.1 117 114 117 116 ± 1.7
B6BALB.B
3 0 0 0 0 0 0 0 0
*CFU-GM indicates colony-forming unit-granulocyte/macrophage; CFU-IL-3, colony-forming unit-interleukin-3.
†Cultures (triplicate) contained 1  105 spleen cells obtained from recipient mice (2 per group) 5 days after bone marrow transplantation.
‡Recipient mice were primed 24 days before transplant with 3.2  107 C3H.SW spleen and lymph node cells.
§Recipient mice were primed 35 and 24 days before transplant with 4  107 and 3.2  107 C3H.SW spleen and lymph node cells, respectively.
Recipient mice were primed 1 time with 3  107 BALB.B spleen and lymph node cells 40 days before transplant.
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bility antigens (MiHA) and (2) is transferable by peripheral
Thy1.2+ (CD3+) NK1.1– cells from primed recipients.
FasL-Defective Mice Effectively Resist MHC-Matched
Marrow Allografts
The requirement for FasL-mediated function in the
allograft resistance by primed recipients was examined
using FasL-defective B6-gld/gld mice. Groups of FasL-
defective and FasL normal B6 mice were primed to
C3H.SW alloantigens 3 weeks before BMT. Spleen cells
from B6-gld/gld and B6 recipients not primed to donor
alloantigens contained significant numbers of CFU-GM
(Figures 3 and 4). In contrast, both FasL-defective and nor-
mal recipients primed to donor antigens contained virtually
no CFU-GM (Figure 3). To more carefully compare the
2 recipient groups, higher numbers of marrow cells were
transplanted (Figure 4). Significant numbers of colonies
were present in cultures of spleen cells from both B6-
gld/gld and B6 recipients after transplantation of 1  107
TCD bone marrow cells (Figure 4). Therefore, the resis-
tance that was present in both groups of 1 primed recipi-
ents was overridden at this same cell dose. In summary,
these ﬁndings demonstrated that no difference was detected
in any experiment comparing the resistance in non-MHC
alloantigen primed FasL-defective and wild-type recipients.
Perforin-Deficient Mice Effectively Demonstrate
Marrow Allograft Resistance
Normal B6 and perforin-deﬁcient B6 (B6-perf –/–) mice
were primed to C3H.SW alloantigens before BMT with
C3H.SW marrow. High numbers of CFU-GM and CFU-
IL-3 were generated by spleen cells from both unprimed B6
and unprimed perforin-deﬁcient recipients (Table 3). Virtu-
ally no CFU-GM or IL-3 was produced by spleen cells from
B6 primed recipients. A few CFU-GM and IL-3 were
detected in cultures from the primed perforin-deficient
mice; however, comparison of these numbers to the CFU
numbers observed after transplant in naive B6 perf –/– recipi-
ents indicated that B6-perf –/– primed recipients exhibited
strong resistance.
Because the kinetics of priming may be different in per-
forin-deficient mice, the priming regimen was altered by
extending the time period after priming and increasing the
number of priming events before BMT. When the time
period after priming was extended to 5 (versus 3) weeks
before BMT, no CFUs were detected in perforin-defi-
cient recipients after BMT with 2  106 TCD C3H.SW
marrow (Table 4). Moreover, both the normal B6 and B6-
perf –/– recipients primed in this manner exhibited complete
resistance after transplantation with greater numbers (1 
107 TCD) of donor marrow cells (Table 4). A similar result
was observed in perforin-deficient marrow recipients who
were primed with 2 independent injections of C3H.SW
cells (Figure 5). Spleen cells from B6-perf –/–C3H.SW and
B6C3H.SW mice contained no detectable CFU-GM after
transplantation. These ﬁndings demonstrated that perforin-
deﬁcient recipients were capable of mediating strong resis-
tance to MHC-matched marrow allografts.
Allograft Resistance Is Specific for Committed
Progenitor Cells Expressing Non-MHC Donor MiHA
Regardless of the effector pathway(s) involved in the resis-
tance observed, it was important to determine if the molecular
pathway activated after BMT was speciﬁc only for the marrow
Table 2. Marrow Graft Resistance Is Transferrable to Nonresistant Mice*
B6 Cells Column Transplanted CFU-GM/Well Average
BMT Recipients† Transferred‡ Passaged§ TCD Marrow 1 2 3 CFU-GM ± SD
Experiment 1
B6naive None No C3H.SW 207 246 200 223 ± 20.2
B6C3H.SW None No C3H.SW 0 0 0 0
B6naive B6naive No C3H.SW 232 214 167 204.3 ± 33.6
B6naive B6C3H.SW No C3H.SW 20 14 8 14 ± 6
Experiment 2
B6naive B6naive No C3H.SW 89 121 116 108.7 ± 17.2
B6C3H.SW B6naive No C3H.SW 3 3 0 2 ± 1.7
B6naive B6C3H.SW No C3H.SW 0 0 1 0.3 ± 0.6
B6naive B6C3H.SW Yes C3H.SW 0 1 2 1 ± 1
Experiment 3
B6naive B6naive No C3H.SW 122 147 128 132.3 ± 13.1
B6C3H.SW B6naive No C3H.SW 0 1 0 0.3 ± 0.6
B6naive B6C3H.SW Yes C3H.SW 20 13 20 17.7 ± 4.0
*BMT indicates bone marrow transplantation; TCD, T cell–depleted; CFU-GM, colony-forming units granulocyte/macrophage.
†Recipient mice were either naive B6 (B6naive) or B6 mice primed 2 times against C3H.SW donor antigens (B6C3H.SW).
‡In Experiment 1, mice used as donors for adoptive transfer of resistance were killed 2 days before BMT. Spleen and lymph node cells (7.5 
107) were prepared and injected intravenously into normal B6 recipients. One day later, the mice were administered 9.0 Gy total body irradia-
tion. One day after irradiation, the animals received bone marrow intravenously. In experiments 2 and 3, 2  107 and 1.5  107 CD3+ cells were
transferred, respectively.
§The percentage CD3+ cells in the transferred populations were as follows: experiment 2: B6naive, 41.6%; B6C3H.SW not column passed, 34.0%;
B6C3H.SW column passed, 82.0%; experiment 3: B6naive, 41.0%; B6C3H.SW column passed, 93.7%.
All recipients were transplanted with 2  106 C3H.SW BM-TCD.
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progenitor cell populations of donor origin. Groups of B6naive
and B6C3H.SW mice were given bone marrow containing either
donor C3H.SW or B6-Ly5.1 congenic marrow (Table 5). As
predicted, CFU-GM was present in spleens from B6 naive
mice transplanted with either marrow inoculum (Table 5). B6
primed recipients transplanted with 2  106 or 1  106 syn-
geneic B6-Ly5.1 marrow–TCD also contained CFU-GM,
demonstrating that resistance was not elicited after transplan-
tation of syngeneic marrow (Table 5). In contrast, resistance
against donor C3H.SW marrow was induced in these mice by
transplantation of C3H.SW marrow (Table 5). To determine if
the resistance (after its induction) was speciﬁc for donor pro-
genitor cells, equal numbers of C3H.SW and B6-Ly5.1 mar-
row cells were injected. CFU-GM were identiﬁed in these
recipients (Table 5). Notably, the number of CFU obtained
was equivalent to the number detected when B6-Ly5.1 mar-
row was injected alone at the same cell concentration (Table
5). To deﬁnitively ascertain if the CFUs present after mixed
marrow BMT were of donor allogeneic C3H.SW or syn-
geneic B6 origin, cells from the colonies of mixed-marrow
recipients and control recipients (Table 5) were obtained after
methylcellulose digestion of these cultures and stained for
Ly5.1 expression (Figure 6). All cells derived from the colonies
obtained from B6naive mice after transplantation with C3H.SW
marrow (Figure 6A) were Ly5.1– as predicted, whereas those
cells derived from the colonies obtained from B6C3H.SW mice
(Figure 6B) after transplantation with B6-Ly5.1 marrow were
virtually all Ly5.1+. Importantly, all cells produced from the
colonies obtained after mixed Ly5.2 (C3H.SW) and Ly5.1
(B6) marrow transplantation into B6C3H.SW (Figure 6C) recipi-
ents were Ly5.1+. These ﬁndings demonstrated that after elici-
tation of resistance in the recipient by donor marrow (ie,
C3H.SW), the effector pathway induced was highly speciﬁc
for MiHA expressed on the donor C3H.SW but not syngeneic
B6 progenitors.
DISCUSSION
Higher incidences of graft failure after BMT, using T cell–
depleted marrow to avoid GVHD, and frequent rejection in
multiply transfused transplant recipients have engendered
signiﬁcant clinical concerns regarding graft rejection. Drug
and/or radiation treatment to suppress host lymphoid func-
tion is generally required to prevent rejection of
marrow/progenitor cell allografts even when transplantations
are performed between HLA-matched donor-recipient pairs
[5,20]. The present investigation developed a murine model
Figure 2. B6 mice were primed 1 time against BALB.B antigens
4 weeks before use for adoptive transfer. Colony-forming unit-inter-
leukin-3 (CFU-IL-3) was not detected in spleen cell cultures from
these mice after bone marrow transplantation (BMT) with 2  106
BALB.B T cell–depleted marrow (data not shown). Natural killer
(NK) cell depletion was achieved by injection of PK136 mAb into
B6BALB.B primed mice 3 days before collection of cells for adoptive
transfer (see “Materials and Methods”). Spleen and lymph node cells
from B6BALB.B mice untreated and treated with anti-NK1.1 monoclo-
nal antibody were obtained on the day of the adoptive transfer and
stained with anti-CD3 ﬂuorescein isothiocyanate to determine T-cell
concentration. Aliquots containing 2  107 CD3+ cells were depleted
as described in “Materials and Methods.” Populations from B6naive or
B6BALB.B mice were infused into B6naive recipients (2 per group)
48 hours before total body irradiation. On day –1, all recipients were
irradiated (9.0 Gy), and on day 0, recipients received a BMT contain-
ing 2  106 BALB.B BM-TCD. Naive unfractionated versus primed
unfractionated and primed NK1.1–: P = .0063 and .0084, respectively.
Figure 3. Analysis of the requirement for FasL-mediated function in
primed marrow allograft resistance. B6 and B6-gld/gld mice were
primed 1 time against C3H.SW antigens 3 weeks before bone marrow
transplantation. At day –1, naive and primed recipient mice (2 per
group) received total body irradiation (9.0 Gy) and were subsequently
infused with 2  106 C3H.SW T cell–depleted marrow 24 hours later
(day 0). Five days later, spleen cells were assessed for colony-forming
unit-granulocyte/macrophage (CFU-GM) activity.
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based on a previously described canine system in which a
radioresistant mechanism was used by recipients to resist
MHC-matched MiHA disparate marrow engraftment
[19,21,22]. Experimental findings from the present study
have demonstrated that host resistance to MHC-matched
marrow allografts after priming to donor MiHA antigens is
highly speciﬁc for progenitor cells expressing donor antigens
and is mediated by CD3+ Thy1+ NK1.1– cells. Observations
from both clinical and experimental investigations have been
consistent with an important role for host antidonor cyto-
toxic T cells in resistance to marrow grafts after BMT [15-
17]. In the studies reported here, cytotoxically impaired
recipients unable to mediate perforin-dependent cytotoxicity
efﬁciently resisted marrow allografts, as did recipients unable
to effect CD95L-dependent killing. These ﬁndings demon-
strate that resistance can be mediated independently by
either pathway alone, or other cytotoxic and/or noncytotoxic
effector modalities can effect resistance. The present obser-
vations therefore suggest that potential strategies designed to
target either host cytotoxic function to facilitate allogeneic
marrow engraftment may provide limited beneﬁt.
The acute rejection of allogeneic marrow can occur
within several days of transplantation in irradiated recipients
[6]. In a previous study, we found that 9.0 Gy–treated cyto-
toxically impaired B6 mice lacking perforin or FasL func-
tion were capable of resisting MHC class I/II–mismatched
allogeneic marrow grafts [18]. Studies by Bennett and others
[7-11,23,24] have demonstrated that acute rejection after
fully allogeneic and P → F1 transplantations involving
unsensitized mice can involve NK/CD8+ and T/NK popula-
tions. Two observations in the present model supported a
role for T-cell populations but not NK cell populations.
First, resistance required a priming event and was targeted
against MHC-matched progenitor cells. Recognition of
self-MHC class I could also inhibit NK-cell function in such
a rejection process [25]. In addition, after transplantations of
cells containing a mix of donor marrow together with syn-
geneic marrow, only progenitor populations expressing
donor antigens present on the priming inoculum were
rejected. Nonetheless, T-cell populations expressing NK
markers could have been contributory. Enriched popula-
tions of CD3+ T cells efficiently transferred resistance.
Table 4. Perforin-Deﬁcient Recipients Mediate Highly Efﬁcient Resistance
After Augmented Priming*
Average Number
Transplanted TCD CFU/Well ± SD‡
BMT Recipients Marrow (2  106) CFU-IL-3 CFU-GM
B6naive 2 114.0 ± 9.0 73.0 ± 17.4
B6C3H.SW† 2 <1 <1
B6-perf –/–naive 2 136.7 ± 29.4 134.7 ± 17.9
B6-perf –/–C3H.SW† 2 <1 <1
B6naive 10 326.5 ± 24.7 ND
B6C3H.SW† 10 <1 ND
B6-perf –/–naive 10 407.5 ± 55.9 ND
B6-perf –/–C3H.SW† 10 <1 ND
*BMT indicates bone marrow transplantation; TCD, T cell–depleted;
CFU-IL-3, colony-forming units-interleukin-3; CFU-GM, colony-
forming unit-granulocyte/macrophage; ND, not done.
†Mice were primed 36 days before BMT with 35  106 C3H.SW
spleen and lymph node cells.
‡Data are presented as the average CFU-IL-3 and GM ± SD of tripli-
cate cultures established from spleen cells pooled from 2 to 3 animals
per group 5 days after BMT.
Table 3. Perforin-Deﬁcient Primed Recipients Mediate Strong Allograft
Resistance*
Average Number
Transplanted TGD CFU/Well ± SD‡
BMT Recipients Marrow (2  106) CFU-IL-3 CFU-GM
B6naive C3H.SW 136.7 ± 30.1 122.6 ± 28.5
B6C3H.SW† C3H.SW <1 <1
B6-perf –/–naive C3H.SW 267 ± 30.1 187.3 ± 18.3
B6-perf –/–C3H.SW† C3H.SW 15 ± 3 15.7 ± 2.1
*BMT indicates bone marrow transplantation; TCD, T cell–depleted;
CFU-IL-3, colony-forming units-interleukin-3; CFU-GM, colony-
forming unit-granulocyte/macrophage.
†Mice were primed 22 days before BMT with 35  106 C3H.SW
spleen and lymph node cells.
‡Data are presented as the average CFU-IL-3 and GM ± SD of tripli-
cate cultures established from spleen cells pooled from 2 to 3 mice per
group 5 days after BMT.
Figure 4. Analysis of FasL-dependent function of allograft resistance
after transplant with varying numbers of donor marrow. B6 and
B6-gld/gld mice were primed 1 time against C3H.SW antigens 3 weeks
before bone marrow transplantation. At day –1, naive and primed
recipient mice (2 per group) received total body irradiation (9.0 Gy)
and were subsequently infused with 2  106 () or 1  107 ()
C3H.SW T cell–depleted marrow 24 hours later (day 0). Five days
later, spleen cells were assessed for colony-forming unit-
granulocyte/macrophage (CFU-GM) activity as described. Cultures
from B6naive and B6-gld/gldnaive mice transplanted with C3H.SW
T cell–depleted marrow (2  106) contained 80.7 ± 35 and 146.3 ± 10
CFU-GM, respectively.
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However, when Thy1.2- but not NK1.1-expressing cells
were deleted before transfer, resistance activity was abro-
gated, demonstrating that CD3+ Thy1+ NK1.1– cells likely
mediate the resistance against MiHA disparate progenitor
populations.
Previous studies have attempted to directly detect a role for
cytotoxic function in “barrier” activity. Perforin-deﬁcient mice
maintained in a conventional, but not speciﬁc pathogen-free,
facility were reported to show some loss in the (NK-depen-
dent) capacity to reject class I–deﬁcient marrow grafts. In con-
trast, B6-gld/gld recipients demonstrated no difference from
wild-type recipients [26]. However, using progenitor graft
models that involved resistance contributions by multiple bar-
rier cell populations, granzyme B–deﬁcient as well as perforin-
or CD95L-deﬁcient recipients failed to exhibit diminished bar-
rier function [18,27]. Direct cytotoxicity of progenitor cells by
NK cells could also not be detected [28]. To begin to address
the contributions of cytotoxic function by T cells in the resis-
tance observed in the present studies, recipients deﬁcient in
perforin or FasL function were assessed for their capacity to
prevent initial MiHA disparate progenitor cell engraftment.
The ﬁndings demonstrated that the resistance in a T cell–
dependent model in primed recipients singularly lacking either
of these cytotoxic pathways did not differ signiﬁcantly from
wild-type primed recipients. These observations may reﬂect
that either pathway individually can compensate for the
absence of the other or that neither group of molecules is func-
tionally required for the resistance process. Our recent results
examining recipients lacking both pathways indicate that non-
perforin- and CD95L-mediated pathways can effect resistance
in this model (M.K., M.J., M. Mammolenti, R. Jurecic, R.B.L.,
unpublished data). In addition to tumor necrosis factor (TNF)
receptors, other death domain–containing members of this
family, including DR3, DR4, and DR5, have been identiﬁed
that can induce target cell apoptosis via caspase activation [29-
34]. These receptors are richly expressed in the lymphohe-
matopoietic compartment, although their expression on pro-
genitor cells is currently unknown [29-32]. Thus, cell-mediated
cytotoxic function by effector cells expressing TNF, TWEAK,
and TRAIL remains a potential pathway in the present model.
Notably, transplantation of mixed marrow inoculum
demonstrated that the pathway effecting resistance was spe-
ciﬁc only for progenitors expressing 1 or more populations of
donor antigens. Previous studies using anti H-Y and
anti–minor H antigen CTL lines in vitro found that H-Y anti-
gens and some minor H antigens are expressed in some pro-
genitor cell populations [35,36]. This study investigated resis-
tance in vivo and examined more lineage-committed
progenitors, ie, CFU cells. A question that needs to be
addressed is whether more primitive, ie, more multipotential,
progenitors express the same partially overlapping or different
antigens. At least one study did identify H-Y expression in
vitro on a multilineage (granulocyte, erythrocyte, monocyte,
macrophage [CFU-GEMM]) population [35]. Interestingly,
analysis of in vitro CTL responses by H-2b mice, the recipient
strain used in the studies reported, demonstrated a pattern of
response against a subset of so-called “immunodominant”
BALB/c minor H antigens [37]. When such immunodomi-
nant minor antigens are expressed, CTL responses to such
antigens obscure responses to so-called second-order antigens.
Figure 5. Analysis of perforin-dependent host function in allograft
resistance after multiple priming to donor antigens. B6C3H.SW and B6-
perf –/–C3H.SW mice were primed with C3H.SW spleen and lymph node
cells 61 and 26 days before transplantation with 2  106 C3H.SW 
T cell–depleted marrow cells. Recipient spleen cells were assayed at day
5 for colony-forming unit-granulocyte/macrophage (CFU-GM) activity.
Table 5. Induction and Speciﬁcity of Resistance After Mixed Bone Marrow Transplantation*
BMT TCD-BMT CFU-GM Average
Recipients (Ly5.2) Inoculum Cell Number (106) Experiment 1 Experiment 2 Experiment 3 CFU-GM ± SD
B6naive B6-Ly5.1 2 113 115 121 116.3 ± 4.2
B6naive C3H.SW (Ly5.2) 2 150 153 178 160.3 ± 15.4
B6C3H.SW† B6-Ly5.1 2 159 203 206 189.3 ± 26.3
B6C3H.SW† B6-Ly5.1 1 32 38 30 33.3 ± 4.2‡
B6C3H.SW† C3H.SW (Ly5.2) 2 0 0 0 0
B6C3H.SW† B6-Ly5.1 plus 1 31 40 60 43.7 ± 14.8‡
C3H.SW (Ly5.2) 1
*BMT indicates bone marrow transplantation; TCD, T cell–depleted; CFU-GM, colony-forming unit-granulocyte/macrophage.
†B6 mice were primed 2 times against C3H.SW antigens by inoculation of 3  107 spleen and lymph node cells intraperitoneally and subcutaneously.
‡The difference between these 2 values was not statistically signiﬁcant; P = .31.
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In contrast to such in vitro CTL responses, GVHD responses
between B6 and BALB recombinant strains were not found to
correlate with this pattern of CTL immunodominance [38]. It
will be interesting to determine if the pattern of graft rejection
against these MiHA-disparate strains follow the in vitro
(CTL) or in vivo (GVHD) pattern, because the present ﬁnd-
ings indicate that one or more cytotoxic pathways are not
required in the resistance observed.
As noted above, the molecular “arsenal” of the effector
cells providing barrier function could include any or a com-
bination of the cytotoxins including perforin, granzyme B,
and FasL as well as TRAIL and TWEAK [31,32,34,39,40].
However, the fate of various progenitor populations in a
resistant recipient remains unclear. Some or all progenitor
populations may be killed; alternatively, some may survive.
The inhibition of progenitor function (eg, proliferation) and
differentiation would also result in the resistance phenotype
observed in these studies. Thus, cytokines previously
demonstrated to inhibit hematopoiesis, including TNF-
[41,42], transforming growth factor (TGF)-1 [42-44],
TGF3 [45], and macrophage inﬂammatory protein-1 [42],
could be contributory to resistance in both cytotoxically
deﬁcient and normal recipients. Investigation of death and
cytokine receptors in progenitor cell populations should
help to identify the effector ligand(s) that participate in bar-
rier responses. In summary, the present and previous studies
using cytotoxic-impaired mice have not identiﬁed defects in
several models of marrow graft resistance. Thus, although
CTL have been identiﬁed in resistant individuals undergo-
ing clinical and experimental marrow graft rejection, the
question persists regarding the role of cytotoxic effector
molecules in this process.
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